Kornimate/medical-research-clean huggingface dataset:
imaginal exposure for hoarding disorder

Conditions: Hoarding Disorder

Summary: the present study will test a potential new treatment strategy, imaginal exposure, for hoarding disorder. although cognitive behavioral therapy often reduces hoarding, some people do not want to start, or cannot handle, that option. to help such individuals, the present study will provide imaginal exposure therapy to people with hoarding disorder, wherein they imagine discarding possessions as a way of becoming acclimated to the idea. we predict that imaginal exposure will improve hoarding symptoms as well as two psychological experiences linked to the condition: intolerance of uncertainty and emotional avoidance.

hoarding disorder is a common mental illness characterized by difficulty parting with possessions and by clutter that makes living spaces unusable. cognitive behavioral therapy (cbt) is an effective treatment for hoarding disorder, but new approaches are needed to engage those who are reluctant to start or cannot tolerate cbt. both intolerance of uncertainty and emotional avoidance are linked to hoarding disorder and may interfere with treatment engagement. imaginal exposure, a therapeutic technique which involves repeatedly imagining feared scenarios and experiencing the evoked emotions, effectively targets both intolerance of uncertainty and emotional avoidance. the present study is the first to test whether imagining discarding possessions can improve hoarding symptoms more than does a control exercise. we hypothesize that compared to a control exercise, imaginal exposure will improve hoarding symptoms, intolerance of uncertainty and emotional avoidance.

Eligibility criteria:
inclusion criteria: 1. age 18 and older 2. any gender and all ethno-racial categories 3. hoarding disorder primary condition 4. willing and able to understand and complete consent and study procedures 5. english speaking exclusion criteria: 1. severe depression 2. clinically at risk of suicide with columbia suicide severity rating scale (c-ssrs) suicidal ideation subscale of 4 or higher (i.e. suicidal intent without specific plan) 3. currently receiving cognitive behavioral therapy (cbt)

Keywords: hoarding disorder intolerance of uncertainty experiential avoidance imaginal exposure clutter attachment
to evaluate the efficacy of three times weekly (tiw) vadadustat compared to standard of care esa in patients with anemia of ckd receiving in-center hemodialysis

Conditions: Anemia of Chronic Kidney Disease

Summary: this is a multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the efficacy of vadadustat administered three times a week compared to standard of care erythropoiesis-stimulating agent for the treatment of anemia in in-center hemodialysis participants with end-stage kidney disease (eskd). the total duration of the study is approximately 33 weeks including screening and follow-up.


Eligibility criteria:
inclusion criteria: * adult participants ≥18 years of age. * receiving outpatient in-center hemodialysis for eskd at least three times a week. * currently prescribed or meets criteria for esa based on approved facility policy. * hb \> 8 grams per deciliter (g/dl). * serum ferritin ≥100 nanograms per milliliter (ng/ml) and transferrin saturation (tsat) ≥20%. * understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure. exclusion criteria: * contraindication to receive vadadustat per united states prescribing information (uspi) as determined by the treating health care provider. * concomitant use of any hypoxia-inducible factor prolyl hydroxylase inhibitor(hif-phi). * known cirrhosis or active, acute liver disease. * unable to comply with study requirements or compliance with attending dialysis treatments as prescribed, or in the opinion of the treating physician or investigator, not clinically stable to participate in the study. * pregnant at the time of consent (per participant self-report). * any other reason, which in the opinion of the investigator, would make the participants unsuitable for participation in the study.

Keywords: chronic kidney disease hemodialysis erythropoiesis-stimulating agent open-label vadadustat
prodigy, a level 2 sleep study device, validation study

Conditions: Sleep Apnea

Summary: the prodigy system, developed by cerebra medical ltd, allows for the generation of the same information in the home that is currently only obtained in in-laboratory studies. the objective of the current study is to demonstrate that the signals obtained by this comprehensive, portable system are comparable to those obtained in in-laboratory studies.

this study consists of obtaining standard polysomnography signals concurrently by the prodigy 2 and by the standard commercial systems used in the sleep disorders clinic (alice g3) in hamilton, on and the st. charles sleep disorders center (nihon kohden) in port jefferson, ny. 42 patients will be recruited from each of the two sites, for a total of 84 patients. questionnaires on demographics and mental health, including the depression anxiety stress scale-21, questionnaires on sleep and fatigue including pittsburgh sleep quality index, insomnia severity index, and epworth sleepiness scale and questionnaires on quality of life including the functional outcomes of sleep questionnaire-10 (fosq-10) and the euroquol 5d-5l will be completed online using a survey platform (qualtrics or redcap).

Eligibility criteria:
inclusion criteria: * patients undergoing a diagnostic sleep test exclusion criteria: * in-hospital patients * subjects who self-report a previous diagnosis of neuromuscular disorders, obesity hypoventilation, or severe lung disease * subjects who are not fluent in english, or who have special communication needs * subjects who have dementia/alzheimer's disease * subjects with comorbid violent parasomnias * subjects requiring additional assistance or who have limited ability follow commands.

Keywords: prodigy
cryoablation of low risk small breast cancer- ice3 trial

Conditions: Breast Cancer

Summary: to evaluate the efficacy of cryoablation without lumpectomy and its impact on local and distant recurrence of early stage breast cancer .


Eligibility criteria:
inclusion criteria: 1. competent to sign informed consent 2. diagnosis of invasive ductal breast carcinoma by core needle biopsy, meeting the following criteria: 1. unifocal primary disease note: patients with multifocal and/or multicentric in breast cancer, or evidence of eic are not eligible. patients with contralateral disease will remain eligible. 2. tumor size ≤1.5 cm in greatest diameter in the axis parallel to the treatment probe and ≤1.5 cm in the axis anti-parallel to the treatment probe and ≤1.5 cm in anterior/ posterior dimension. tumor size ≤1.5 cm in greatest diameter as measured by breast ultrasound, mammogram and/or mri. the largest dimension measured will be used to determine eligibility. 3. nottingham grade 1-2. specifically, nuclear and mitotic scores must be less than or equal to 2. 4. estrogen receptor-positive, progesterone receptor-positive, her2 negative 3. age\>= 50 4. breast size adequate for safe cryoablation 5. lesion must be sonographically visible at the time of treatment. 6. history of previously treated ipsilateral or contralateral breast carcinoma is not an exclusion criteria if the investigator is certain newly diagnosed carcinoma is new unifocal primary tumor. exclusion criteria: 1. presence of lobular carcinoma 2. presence of luminal b pathology 3. nottingham score of 3 (specially nuclear and mitotic score\>2) 4. presence of microinvasion, or invasive breast carcinoma with extensive intraductal component (eic) 5. presence of multifocal and/or multicentric in breast cancer 6. presence of multifocal calcifications 7. presence of prior or concurrent neoadjuvant chemotherapy for breast cancer 8. presence of prior en bloc open surgical biopsy and/or lumpectomy for diagnosis/treatment of the index breast cancer 9. patient that is not suitable to cryoablation procedure according to the physician opinion 10. er and pr negative, or her2 positive noted on pre-cryo biopsy

Keywords: cryoablation, cryotherapy, breast cancer
genome driven primary care clinics - an rct

Conditions: Health Services Administration; Genetic Predisposition; Microbial Colonization

Summary: a cluster randomized controlled study of 40 primary care clinics in northern israel (20 intervention clinics, 20 usual care clinics) to evaluate the value of introducing a precision medicine/genomic approach/paradigm on the clinical and economical outcomes of the clinics. intervention includes 3 elements: 1. dna extraction and evaluation (up to the level of wgs); 2. feces sample for microbiome study, 3. wearable devices for continuous monitoring of body functions. expected number of participants is 100,000 in each arm. results will be calculated for a clinic as a unit and not for individuals (each clinic to be compared to "twin" selected clinic).

study major aim: assess whether employing a paradigm of genomic/precision medicine in primary care clinics can lead to an improvement in the medical or economic outcomes of the clinic as a unit. specific and secondary aims 1. study differences in morbidity, mortality, quality of life or the cost of medical service indicators between clinics operating under a genome driven paradigm compared to usual care clinics. 2. examine whether the public has an interest in extensive genetic testing. 3. examine whether the medical staff has an interest and ability to assimilate a genomic approach in the routine clinic work. 4. identify links between genetic markers (mutations, variants) and different diseases (incidence or clinical behavior) or different drug responses (resistance, effectiveness, side-effects). 5. examine whether the implementation of prolonged personal monitoring devices will lead to improved morbidity and mortality indices. 6. examine whether measuring genomic variability in the microbiome has implications on health status or means of coping with different diseases and different health conditions.

Eligibility criteria:
inclusion criteria: * all clinic adult population * all diseases exclusion criteria: * mentality unable to understand and sign consent

Keywords: wearable monitors, microbiome, genomic medicine,
a study of alisertib in patients with extensive stage small cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: puma-ali-4201 is a phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (sclc) following progression on or after treatment with one platinum-based chemotherapy and anti-pd-l1 immunotherapy agent. up to one additional systemic anti-cancer therapy for sclc is allowed, for a total of up to two prior lines of therapy. this study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.


Eligibility criteria:
inclusion criteria: * aged ≥18 years at signing of informed consent * pathologically confirmed sclc * prior treatment with one platinum-based chemotherapy and an anti-pd-l1 immunotherapy. up to one additional systemic anti-cancer therapy for sclc is allowed, for a total of up to two prior lines of therapy exclusion criteria: * prior treatment with an aurka specific-targeted or pan-aurora-targeted agent, including alisertib in any setting note: there are additional inclusion and exclusion criteria. the study center will determine if you meet all of the criteria.

Keywords: alisertib sclc
home-based exercise training during covid-19 pandemic in post-bariatric

Conditions: Bariatric Surgery; Obesity

Summary: the aim of this study is to assess the effect of a home-based exercise training during social isolation due to covid-19 pandemic in patients who undertook bariatric surgery.

eligible patients will be invited to participate in the study by phone call. the research team will visit the included patients. all patients giving the written consent will perform the following tests before being randomly allocated into exercise training or control: 1) blood pressure; 2) anthropometric measures; 3) blood sampling; 4) handgrip test; 5) sit and stand test; 6) exercise capacity; 7) nutritional recalls and 8) health-related questionnaires. patients will be randomized in a 1:1 ratio to control group (will receive information to keep active and eating healthy) or exercise training group (will receive a telemonitored exercise program through video conference, three times a week, during 3 months). following 3 months of intervention, the outocomes will be re-assessed.

Eligibility criteria:
inclusion criteria: * men and women submitted to bariatric surgery in the last 12 months. * not engaged in regular exercise training programs. exclusion criteria: * patients with \>12 months of post-operatory period. * patients with diagnosed mental disorders. * patients with physical limitations or not allowed by the physician to exercise. * patients infected with covid-19 at the time of data collection.
validation of a diagnostic self-assessment scale non-motor fluctuations at the parkinson's patient

Conditions: Parkinson Disease

Summary: the objective of this study is to validate a diagnostic tool severity of these common non-motor manifestations, disturbing and little recognized as a self-questionnaire. this assessment tool used on different subgroups of patients (free from any treatment at an early stage of the disease and the stage of motor complications) will better understand the natural history of the non-motor fluctuations (fnm)


Eligibility criteria:
inclusion criteria: patient aged 30 or over patient having an parkinson's disease patient hospitalized in one of the clinical sites participating in the project patient have agreed to participate in the study subject that masters the french language and able to fulfill the self-questionnaire. exclusion criteria: patient aged under 30 patient can not answer the self-administered questionnaire patient has not agreed to participate in the study.
chlorpheniramine nasal spray to accelerate covid-19 clinical recovery in an outpatient setting: accros-i

Conditions: COVID-19; Symptoms and Signs; COVID-19 Pandemic; Coronavirus Disease 2019; Coronavirus Infections

Summary: the goal of this clinical trial is to examine the effectiveness of intranasal-administered chlorpheniramine maleate in covid-19-positive participants as part of early treatment for covid-19. the main questions it aims to answer are: * to assess the efficacy of nasal spray with chlorpheniramine (1.0%) for improving clinical recovery in covid-19 patients. * to assess the efficacy, safety, and tolerability of nasal spray with chlorpheniramine (1%) as an adjunct to the standard of care in reducing hospitalizations and improving clinical recovery in adult patients with mild covid-19.

the main goal of the present study is to examine the effectiveness of cpm intranasal spray as part of early treatment for covid-19. the study will test the hypothesis that intranasal cpm would accelerate clinical recovery, particularly the alleviation of sensory symptoms and urs, in patients with covid-19.

Eligibility criteria:
inclusion criteria: * male or female patients between 18 and 65 years (both inclusive) * patients with positive rt-pcr test for sars-cov-2 in nasopharyngeal or oropharyngeal swabs (sample collected or proof of positive test ≤3 days before randomization) * patients with mild covid-19 have the following symptoms and signs prior to randomization (≤ 3days) * upper respiratory tract symptoms (\&/or fever) without shortness of breath or hypoxia. (spo2 \> 94 %) * willingness to sign written informed consent document exclusion criteria: * \< 18 years of age * hospitalized patients * subject with known allergy or hypersensitivity to the components of the formulation. * patients receiving therapy with monoamine oxidase inhibitors (maois): rasagline, selegiline, isocarbonboxasid, phenelzine, tranylcypromine. * patients with narrow-angle glaucoma * urinary retention * sleep apnea * history of immunodeficiency or receiving immunosuppressive therapy. * patients with acute exacerbation of severe comorbidities such as chronic obstructive pulmonary disease (copd), class 3 and 4 heart failure diagnosed according to the criteria of the new york heart failure association (nyha), or diseases with severe oxygenation problems * any surgical procedure in the past 12 weeks * unable to make informed consent or refuse or renounce adherence to standard treatment protocols. * any significant illness or drugs that could interfere with study parameters * any other condition based on the investigator's clinical judgment does not justify the patient's participation in the study. * participation in another clinical trial within the past 30 days * clinically significant arrhythmia or symptomatic cardiac conditions including but not limited to qt elongation * qt interval less than 300 ms or more than 500 ms for both men and women.
alternative care to the accompaniment called "place of respite" in the resolution of the psychotic crises of homeless people with severe mental pathology

Conditions: Mental Health

Summary: document the effectiveness of the "respite site" program in relation to the current health system. document in particular the number and type of constraints, lengths of hospitalization and mode of exit, as well as the exit destination of psychotic homeless people.

between 2012 and 2015, the practice of "stress-related care" related to crisis situations increased by 15%, with about 90,000 people under duress making france one of the european countries where practice most under stress. being homeless, from a visible ethnic minority, combined with the lack of alternatives in the territory are well-documented risk factors for being hospitalized under duress. a review of the 2015 literature has shown that out-of-hospital crisis sites achieve results equivalent to those of conventional hospitalization in terms of reduced symptomatology and would have better outcomes in terms of increase in remission and recovery times of professional activity and social inclusion, with greater efficiency. in marseille, an experimental device has shown its capacity to propose an alternative to hospitalization, for this type of population.running the lessons of this experiment and inspired by the experimentation parachute, a new device experimental, called "place of respite", this place proposes a model of resolution of the psychotic crisis where the person decides the type of care that she wish to receive. it is a device that is therefore an alternative to conventional psychiatric care under duress. the investigators formulate the hypothesis that alternative support to the resolution of the crisis by using the skills of people with disorders severe psychiatric conditions in the experimental "respite site" decreases in the short term the number of hospitalizations and their duration, as well as the experience of the constraint in the course of care of these people, compared to the subjects who did not benefit from this device and could represent a model of crisis management / psychiatric emergency efficient with regard to the current offer.

Eligibility criteria:
inclusion criteria: over 18 years old diagnosed with schizophrenia, bipolar i disorder, or schizoaffective disorder according to the dsmiv classification homeless "ethos 1 or 2" (feantsa classification) in a crisis situation: psychiatric crisis (panss increase of more than 20%), social crisis (significant alteration of social relations) affiliated to a social protection scheme accepting to participate in the study an hcat score greater than or equal to 3 exclusion criteria: under 18 years old participant in another study simultaneously in accordance with article l112112 of the public health code refusing to participate in the study, or whose legal representative refuses to participate in the study in the case of a person under guardianship or curatorship a score on the hcat scale (decision-making competence) strictly less than 3
the effect of ocular rinse volume on surface irritation after intravitreal injections

Conditions: Intravitreal Injection; Ocular Rinse; Age-Related Macular Degeneration; Diabetic Macular Edema; Cystoid Macular Edema

Summary: this is the first randomized controlled trial looking into post-injection rinse volume of standard ophthalmic eyewash and its affect on patient comfort up to 72 hours after injections.

purpose to evaluate whether the volume of wash out rinse after povidone iodine (pi) application for intravitreal injections (ivi) affects patients' ocular surface irritation. methods this was a prospective, single-masked, randomized-controlled trial consisting of 142 subjects . a total of 51, 45, and 46 patients received 3-ml, 10-ml, and 15-ml of ocular rinse respectively. reductions in the ocular surface disease index (osdi) and the standardized patient evaluation of eye dryness ii (speed ii) surveys, conducted before and at 24-72 hours post-injection, were analyzed.

Eligibility criteria:
inclusion criteria: choroidal neovascular membrane or cystoid macular edema requiring intravitreal injections for treatment. exclusion criteria: active ocular infection, eyelid trauma, graft versus host disease, thyroid eye disease, pregnancy.
non-surgical periodontal treatment on hemogram, lipid and glycemic profiles in patients with coronariopathies

Conditions: Periodontitis; Coronariopathy

Summary: objective: the aim of this study was to examine the effects of non-surgical periodontal treatment on the hemogram, glycemic and lipid profiles in cardiopathic patients with an indication for surgical revascularization. materials and methods: twenty-two patients with chronic periodontitis, over 35 years of age (mean age 59.45 years) randomly assigned into 2 groups were evaluated. test group (n=11), received periodontal treatment before the surgical procedure, and control group (n=11), did not received periodontal treatment prior to surgery.


Eligibility criteria:
inclusion criteria: * undergoing cardiovascular treatment; * eight viable teeth in the oral cavity; * four periodontal sites with periodontal probing depths ≥5mm in different teeth. exclusion criteria: -

Keywords: periodontal diseases cardiovascular diseases periodontitis treatment